nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP2D6—Tamoxifen—pancreatic cancer	0.00905	0.203	CbGbCtD
Lisuride—Pericarditis—Fluorouracil—pancreatic cancer	0.00819	0.0216	CcSEcCtD
Lisuride—CYP2D6—Erlotinib—pancreatic cancer	0.00769	0.173	CbGbCtD
Lisuride—Pericardial effusion—Docetaxel—pancreatic cancer	0.00623	0.0164	CcSEcCtD
Lisuride—Pleural effusion—Sunitinib—pancreatic cancer	0.00586	0.0155	CcSEcCtD
Lisuride—Pulmonary fibrosis—Docetaxel—pancreatic cancer	0.00581	0.0153	CcSEcCtD
Lisuride—CYP3A4—Tamoxifen—pancreatic cancer	0.00575	0.129	CbGbCtD
Lisuride—CYP3A4—Erlotinib—pancreatic cancer	0.00489	0.11	CbGbCtD
Lisuride—Pleural effusion—Gemcitabine—pancreatic cancer	0.0047	0.0124	CcSEcCtD
Lisuride—Blood pressure increased—Sunitinib—pancreatic cancer	0.00449	0.0118	CcSEcCtD
Lisuride—CYP3A4—Irinotecan—pancreatic cancer	0.00442	0.0993	CbGbCtD
Lisuride—Pericardial effusion—Epirubicin—pancreatic cancer	0.0042	0.0111	CcSEcCtD
Lisuride—Pericarditis—Epirubicin—pancreatic cancer	0.00399	0.0105	CcSEcCtD
Lisuride—Pericardial effusion—Doxorubicin—pancreatic cancer	0.00389	0.0103	CcSEcCtD
Lisuride—CYP2D6—Doxorubicin—pancreatic cancer	0.0038	0.0854	CbGbCtD
Lisuride—Pericarditis—Doxorubicin—pancreatic cancer	0.00369	0.00973	CcSEcCtD
Lisuride—Dehydration—Erlotinib—pancreatic cancer	0.0035	0.00923	CcSEcCtD
Lisuride—Pleural effusion—Docetaxel—pancreatic cancer	0.00334	0.00881	CcSEcCtD
Lisuride—CYP3A4—Docetaxel—pancreatic cancer	0.00324	0.0728	CbGbCtD
Lisuride—CYP3A4—Sunitinib—pancreatic cancer	0.00322	0.0725	CbGbCtD
Lisuride—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.00315	0.00832	CcSEcCtD
Lisuride—Dehydration—Sunitinib—pancreatic cancer	0.00303	0.00799	CcSEcCtD
Lisuride—Weight increased—Tamoxifen—pancreatic cancer	0.00299	0.00789	CcSEcCtD
Lisuride—Weight decreased—Tamoxifen—pancreatic cancer	0.00298	0.00785	CcSEcCtD
Lisuride—Weight decreased—Erlotinib—pancreatic cancer	0.00294	0.00776	CcSEcCtD
Lisuride—Disorientation—Fluorouracil—pancreatic cancer	0.00287	0.00758	CcSEcCtD
Lisuride—Sweating—Tamoxifen—pancreatic cancer	0.00281	0.00741	CcSEcCtD
Lisuride—Abdominal discomfort—Sunitinib—pancreatic cancer	0.0027	0.00712	CcSEcCtD
Lisuride—Oedema peripheral—Tamoxifen—pancreatic cancer	0.00259	0.00684	CcSEcCtD
Lisuride—Blood pressure increased—Docetaxel—pancreatic cancer	0.00256	0.00674	CcSEcCtD
Lisuride—Weight decreased—Sunitinib—pancreatic cancer	0.00255	0.00672	CcSEcCtD
Lisuride—Dehydration—Irinotecan—pancreatic cancer	0.0025	0.00659	CcSEcCtD
Lisuride—Orthostatic hypotension—Irinotecan—pancreatic cancer	0.00245	0.00647	CcSEcCtD
Lisuride—CYP3A4—Doxorubicin—pancreatic cancer	0.00241	0.0543	CbGbCtD
Lisuride—Mediastinal disorder—Erlotinib—pancreatic cancer	0.00235	0.00619	CcSEcCtD
Lisuride—Mental disorder—Erlotinib—pancreatic cancer	0.00228	0.00602	CcSEcCtD
Lisuride—Malnutrition—Erlotinib—pancreatic cancer	0.00227	0.00598	CcSEcCtD
Lisuride—Pleural effusion—Epirubicin—pancreatic cancer	0.00225	0.00594	CcSEcCtD
Lisuride—Oedema peripheral—Sunitinib—pancreatic cancer	0.00222	0.00586	CcSEcCtD
Lisuride—Weight decreased—Irinotecan—pancreatic cancer	0.0021	0.00554	CcSEcCtD
Lisuride—Cardiac disorder—Sunitinib—pancreatic cancer	0.00209	0.00552	CcSEcCtD
Lisuride—Pleural effusion—Doxorubicin—pancreatic cancer	0.00208	0.0055	CcSEcCtD
Lisuride—Angiopathy—Sunitinib—pancreatic cancer	0.00205	0.0054	CcSEcCtD
Lisuride—Immune system disorder—Sunitinib—pancreatic cancer	0.00204	0.00537	CcSEcCtD
Lisuride—Syncope—Erlotinib—pancreatic cancer	0.00203	0.00536	CcSEcCtD
Lisuride—Mediastinal disorder—Sunitinib—pancreatic cancer	0.00203	0.00536	CcSEcCtD
Lisuride—Cough—Tamoxifen—pancreatic cancer	0.002	0.00527	CcSEcCtD
Lisuride—Sweating—Irinotecan—pancreatic cancer	0.00198	0.00523	CcSEcCtD
Lisuride—Cough—Erlotinib—pancreatic cancer	0.00198	0.00522	CcSEcCtD
Lisuride—Mental disorder—Sunitinib—pancreatic cancer	0.00198	0.00521	CcSEcCtD
Lisuride—Malnutrition—Sunitinib—pancreatic cancer	0.00196	0.00518	CcSEcCtD
Lisuride—Anxiety—Tamoxifen—pancreatic cancer	0.00194	0.00513	CcSEcCtD
Lisuride—Sweating—Gemcitabine—pancreatic cancer	0.00193	0.0051	CcSEcCtD
Lisuride—Anxiety—Erlotinib—pancreatic cancer	0.00192	0.00507	CcSEcCtD
Lisuride—Dry mouth—Tamoxifen—pancreatic cancer	0.00191	0.00503	CcSEcCtD
Lisuride—Infection—Tamoxifen—pancreatic cancer	0.00186	0.0049	CcSEcCtD
Lisuride—Infection—Erlotinib—pancreatic cancer	0.00184	0.00485	CcSEcCtD
Lisuride—Nervous system disorder—Erlotinib—pancreatic cancer	0.00181	0.00479	CcSEcCtD
Lisuride—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00181	0.00477	CcSEcCtD
Lisuride—Anorexia—Tamoxifen—pancreatic cancer	0.00178	0.0047	CcSEcCtD
Lisuride—Oedema peripheral—Gemcitabine—pancreatic cancer	0.00178	0.0047	CcSEcCtD
Lisuride—Anorexia—Erlotinib—pancreatic cancer	0.00176	0.00465	CcSEcCtD
Lisuride—Dehydration—Docetaxel—pancreatic cancer	0.00173	0.00455	CcSEcCtD
Lisuride—Cardiac disorder—Irinotecan—pancreatic cancer	0.00172	0.00455	CcSEcCtD
Lisuride—Cough—Sunitinib—pancreatic cancer	0.00171	0.00452	CcSEcCtD
Lisuride—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00169	0.00447	CcSEcCtD
Lisuride—Insomnia—Tamoxifen—pancreatic cancer	0.00169	0.00446	CcSEcCtD
Lisuride—Angiopathy—Irinotecan—pancreatic cancer	0.00168	0.00444	CcSEcCtD
Lisuride—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00168	0.00443	CcSEcCtD
Lisuride—Immune system disorder—Irinotecan—pancreatic cancer	0.00168	0.00442	CcSEcCtD
Lisuride—Mediastinal disorder—Irinotecan—pancreatic cancer	0.00167	0.00441	CcSEcCtD
Lisuride—Insomnia—Erlotinib—pancreatic cancer	0.00167	0.00441	CcSEcCtD
Lisuride—Dyspnoea—Tamoxifen—pancreatic cancer	0.00167	0.0044	CcSEcCtD
Lisuride—Dyspnoea—Erlotinib—pancreatic cancer	0.00165	0.00435	CcSEcCtD
Lisuride—Angiopathy—Gemcitabine—pancreatic cancer	0.00164	0.00433	CcSEcCtD
Lisuride—Dry mouth—Sunitinib—pancreatic cancer	0.00163	0.00431	CcSEcCtD
Lisuride—Immune system disorder—Gemcitabine—pancreatic cancer	0.00163	0.00431	CcSEcCtD
Lisuride—Mediastinal disorder—Gemcitabine—pancreatic cancer	0.00163	0.0043	CcSEcCtD
Lisuride—Decreased appetite—Tamoxifen—pancreatic cancer	0.00163	0.00429	CcSEcCtD
Lisuride—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00161	0.00426	CcSEcCtD
Lisuride—Fatigue—Tamoxifen—pancreatic cancer	0.00161	0.00425	CcSEcCtD
Lisuride—Decreased appetite—Erlotinib—pancreatic cancer	0.00161	0.00424	CcSEcCtD
Lisuride—Constipation—Tamoxifen—pancreatic cancer	0.0016	0.00422	CcSEcCtD
Lisuride—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.0016	0.00421	CcSEcCtD
Lisuride—Fatigue—Erlotinib—pancreatic cancer	0.0016	0.00421	CcSEcCtD
Lisuride—Infection—Sunitinib—pancreatic cancer	0.00159	0.0042	CcSEcCtD
Lisuride—Constipation—Erlotinib—pancreatic cancer	0.00158	0.00417	CcSEcCtD
Lisuride—Nervous system disorder—Sunitinib—pancreatic cancer	0.00157	0.00414	CcSEcCtD
Lisuride—Anorexia—Sunitinib—pancreatic cancer	0.00153	0.00403	CcSEcCtD
Lisuride—Weight increased—Docetaxel—pancreatic cancer	0.00146	0.00385	CcSEcCtD
Lisuride—Vertigo—Irinotecan—pancreatic cancer	0.00145	0.00383	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—pancreatic cancer	0.00145	0.00383	CcSEcCtD
Lisuride—Syncope—Irinotecan—pancreatic cancer	0.00145	0.00382	CcSEcCtD
Lisuride—Insomnia—Sunitinib—pancreatic cancer	0.00145	0.00382	CcSEcCtD
Lisuride—Dyspnoea—Sunitinib—pancreatic cancer	0.00143	0.00377	CcSEcCtD
Lisuride—Cough—Irinotecan—pancreatic cancer	0.00141	0.00372	CcSEcCtD
Lisuride—Decreased appetite—Sunitinib—pancreatic cancer	0.00139	0.00367	CcSEcCtD
Lisuride—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00138	0.00365	CcSEcCtD
Lisuride—Fatigue—Sunitinib—pancreatic cancer	0.00138	0.00364	CcSEcCtD
Lisuride—Cough—Gemcitabine—pancreatic cancer	0.00137	0.00362	CcSEcCtD
Lisuride—Constipation—Sunitinib—pancreatic cancer	0.00137	0.00361	CcSEcCtD
Lisuride—Asthenia—Tamoxifen—pancreatic cancer	0.00134	0.00354	CcSEcCtD
Lisuride—Confusional state—Irinotecan—pancreatic cancer	0.00133	0.00351	CcSEcCtD
Lisuride—Asthenia—Erlotinib—pancreatic cancer	0.00133	0.0035	CcSEcCtD
Lisuride—Infection—Irinotecan—pancreatic cancer	0.00131	0.00346	CcSEcCtD
Lisuride—Nervous system disorder—Irinotecan—pancreatic cancer	0.00129	0.00341	CcSEcCtD
Lisuride—Infection—Gemcitabine—pancreatic cancer	0.00128	0.00337	CcSEcCtD
Lisuride—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00128	0.00336	CcSEcCtD
Lisuride—Confusional state—Fluorouracil—pancreatic cancer	0.00127	0.00336	CcSEcCtD
Lisuride—Oedema peripheral—Docetaxel—pancreatic cancer	0.00126	0.00334	CcSEcCtD
Lisuride—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00126	0.00332	CcSEcCtD
Lisuride—Anorexia—Irinotecan—pancreatic cancer	0.00126	0.00332	CcSEcCtD
Lisuride—Infection—Fluorouracil—pancreatic cancer	0.00126	0.00331	CcSEcCtD
Lisuride—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00124	0.00328	CcSEcCtD
Lisuride—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00124	0.00327	CcSEcCtD
Lisuride—Dizziness—Tamoxifen—pancreatic cancer	0.00124	0.00326	CcSEcCtD
Lisuride—Tachycardia—Fluorouracil—pancreatic cancer	0.00123	0.00325	CcSEcCtD
Lisuride—Anorexia—Gemcitabine—pancreatic cancer	0.00122	0.00323	CcSEcCtD
Lisuride—Dizziness—Erlotinib—pancreatic cancer	0.00122	0.00323	CcSEcCtD
Lisuride—Anorexia—Fluorouracil—pancreatic cancer	0.0012	0.00318	CcSEcCtD
Lisuride—Insomnia—Irinotecan—pancreatic cancer	0.00119	0.00315	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—pancreatic cancer	0.00119	0.00314	CcSEcCtD
Lisuride—Vomiting—Tamoxifen—pancreatic cancer	0.00119	0.00314	CcSEcCtD
Lisuride—Vomiting—Erlotinib—pancreatic cancer	0.00118	0.0031	CcSEcCtD
Lisuride—Dyspnoea—Irinotecan—pancreatic cancer	0.00118	0.0031	CcSEcCtD
Lisuride—Somnolence—Irinotecan—pancreatic cancer	0.00117	0.00309	CcSEcCtD
Lisuride—Headache—Tamoxifen—pancreatic cancer	0.00117	0.00309	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—pancreatic cancer	0.00116	0.00307	CcSEcCtD
Lisuride—Dehydration—Epirubicin—pancreatic cancer	0.00116	0.00307	CcSEcCtD
Lisuride—Insomnia—Gemcitabine—pancreatic cancer	0.00116	0.00307	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—pancreatic cancer	0.00116	0.00306	CcSEcCtD
Lisuride—Headache—Erlotinib—pancreatic cancer	0.00116	0.00306	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00116	0.00305	CcSEcCtD
Lisuride—Asthenia—Sunitinib—pancreatic cancer	0.00115	0.00303	CcSEcCtD
Lisuride—Decreased appetite—Irinotecan—pancreatic cancer	0.00115	0.00303	CcSEcCtD
Lisuride—Dyspnoea—Gemcitabine—pancreatic cancer	0.00115	0.00302	CcSEcCtD
Lisuride—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.00114	0.00302	CcSEcCtD
Lisuride—Insomnia—Fluorouracil—pancreatic cancer	0.00114	0.00301	CcSEcCtD
Lisuride—Somnolence—Gemcitabine—pancreatic cancer	0.00114	0.00301	CcSEcCtD
Lisuride—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00114	0.003	CcSEcCtD
Lisuride—Fatigue—Irinotecan—pancreatic cancer	0.00114	0.003	CcSEcCtD
Lisuride—Constipation—Irinotecan—pancreatic cancer	0.00113	0.00298	CcSEcCtD
Lisuride—Dyspnoea—Fluorouracil—pancreatic cancer	0.00113	0.00297	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—pancreatic cancer	0.00112	0.00297	CcSEcCtD
Lisuride—Somnolence—Fluorouracil—pancreatic cancer	0.00112	0.00296	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—pancreatic cancer	0.00112	0.00295	CcSEcCtD
Lisuride—Decreased appetite—Gemcitabine—pancreatic cancer	0.00112	0.00295	CcSEcCtD
Lisuride—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00111	0.00293	CcSEcCtD
Lisuride—Fatigue—Gemcitabine—pancreatic cancer	0.00111	0.00292	CcSEcCtD
Lisuride—Constipation—Gemcitabine—pancreatic cancer	0.0011	0.0029	CcSEcCtD
Lisuride—Decreased appetite—Fluorouracil—pancreatic cancer	0.0011	0.0029	CcSEcCtD
Lisuride—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00109	0.00288	CcSEcCtD
Lisuride—Feeling abnormal—Irinotecan—pancreatic cancer	0.00109	0.00287	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—pancreatic cancer	0.00108	0.00284	CcSEcCtD
Lisuride—Dizziness—Sunitinib—pancreatic cancer	0.00106	0.00279	CcSEcCtD
Lisuride—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00106	0.00279	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00106	0.00279	CcSEcCtD
Lisuride—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00104	0.00275	CcSEcCtD
Lisuride—Vomiting—Sunitinib—pancreatic cancer	0.00102	0.00269	CcSEcCtD
Lisuride—Headache—Sunitinib—pancreatic cancer	0.001	0.00265	CcSEcCtD
Lisuride—Syncope—Docetaxel—pancreatic cancer	0.001	0.00264	CcSEcCtD
Lisuride—Palpitations—Docetaxel—pancreatic cancer	0.000987	0.0026	CcSEcCtD
Lisuride—Weight increased—Epirubicin—pancreatic cancer	0.000984	0.0026	CcSEcCtD
Lisuride—Weight decreased—Epirubicin—pancreatic cancer	0.000979	0.00258	CcSEcCtD
Lisuride—Cough—Docetaxel—pancreatic cancer	0.000975	0.00257	CcSEcCtD
Lisuride—Asthenia—Irinotecan—pancreatic cancer	0.000947	0.0025	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—pancreatic cancer	0.00093	0.00245	CcSEcCtD
Lisuride—Sweating—Epirubicin—pancreatic cancer	0.000925	0.00244	CcSEcCtD
Lisuride—Asthenia—Gemcitabine—pancreatic cancer	0.000922	0.00243	CcSEcCtD
Lisuride—Confusional state—Docetaxel—pancreatic cancer	0.00092	0.00243	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—pancreatic cancer	0.000911	0.0024	CcSEcCtD
Lisuride—Infection—Docetaxel—pancreatic cancer	0.000906	0.00239	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—pancreatic cancer	0.000906	0.00239	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—pancreatic cancer	0.000894	0.00236	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—pancreatic cancer	0.00089	0.00235	CcSEcCtD
Lisuride—Dizziness—Irinotecan—pancreatic cancer	0.000872	0.0023	CcSEcCtD
Lisuride—Anorexia—Docetaxel—pancreatic cancer	0.000869	0.00229	CcSEcCtD
Lisuride—Sweating—Doxorubicin—pancreatic cancer	0.000856	0.00226	CcSEcCtD
Lisuride—Oedema peripheral—Epirubicin—pancreatic cancer	0.000853	0.00225	CcSEcCtD
Lisuride—Vomiting—Irinotecan—pancreatic cancer	0.000839	0.00221	CcSEcCtD
Lisuride—Dizziness—Fluorouracil—pancreatic cancer	0.000836	0.0022	CcSEcCtD
Lisuride—Headache—Irinotecan—pancreatic cancer	0.000826	0.00218	CcSEcCtD
Lisuride—Insomnia—Docetaxel—pancreatic cancer	0.000825	0.00218	CcSEcCtD
Lisuride—Vomiting—Gemcitabine—pancreatic cancer	0.000817	0.00216	CcSEcCtD
Lisuride—Dyspnoea—Docetaxel—pancreatic cancer	0.000813	0.00214	CcSEcCtD
Lisuride—Somnolence—Docetaxel—pancreatic cancer	0.000811	0.00214	CcSEcCtD
Lisuride—Headache—Gemcitabine—pancreatic cancer	0.000805	0.00212	CcSEcCtD
Lisuride—Cardiac disorder—Epirubicin—pancreatic cancer	0.000804	0.00212	CcSEcCtD
Lisuride—Vomiting—Fluorouracil—pancreatic cancer	0.000803	0.00212	CcSEcCtD
Lisuride—Decreased appetite—Docetaxel—pancreatic cancer	0.000793	0.00209	CcSEcCtD
Lisuride—Headache—Fluorouracil—pancreatic cancer	0.000792	0.00209	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000789	0.00208	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000787	0.00208	CcSEcCtD
Lisuride—Fatigue—Docetaxel—pancreatic cancer	0.000786	0.00207	CcSEcCtD
Lisuride—Angiopathy—Epirubicin—pancreatic cancer	0.000786	0.00207	CcSEcCtD
Lisuride—Immune system disorder—Epirubicin—pancreatic cancer	0.000782	0.00206	CcSEcCtD
Lisuride—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00078	0.00206	CcSEcCtD
Lisuride—Constipation—Docetaxel—pancreatic cancer	0.00078	0.00206	CcSEcCtD
Lisuride—Mental disorder—Epirubicin—pancreatic cancer	0.000759	0.002	CcSEcCtD
Lisuride—Malnutrition—Epirubicin—pancreatic cancer	0.000754	0.00199	CcSEcCtD
Lisuride—Feeling abnormal—Docetaxel—pancreatic cancer	0.000752	0.00198	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000744	0.00196	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—pancreatic cancer	0.000727	0.00192	CcSEcCtD
Lisuride—Immune system disorder—Doxorubicin—pancreatic cancer	0.000724	0.00191	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000722	0.0019	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—pancreatic cancer	0.000702	0.00185	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—pancreatic cancer	0.000697	0.00184	CcSEcCtD
Lisuride—Vertigo—Epirubicin—pancreatic cancer	0.000677	0.00179	CcSEcCtD
Lisuride—Syncope—Epirubicin—pancreatic cancer	0.000676	0.00178	CcSEcCtD
Lisuride—Palpitations—Epirubicin—pancreatic cancer	0.000666	0.00176	CcSEcCtD
Lisuride—Cough—Epirubicin—pancreatic cancer	0.000658	0.00174	CcSEcCtD
Lisuride—Asthenia—Docetaxel—pancreatic cancer	0.000654	0.00173	CcSEcCtD
Lisuride—Anxiety—Epirubicin—pancreatic cancer	0.000639	0.00169	CcSEcCtD
Lisuride—Dry mouth—Epirubicin—pancreatic cancer	0.000628	0.00166	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—pancreatic cancer	0.000627	0.00165	CcSEcCtD
Lisuride—Syncope—Doxorubicin—pancreatic cancer	0.000625	0.00165	CcSEcCtD
Lisuride—Confusional state—Epirubicin—pancreatic cancer	0.00062	0.00164	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—pancreatic cancer	0.000616	0.00163	CcSEcCtD
Lisuride—Infection—Epirubicin—pancreatic cancer	0.000611	0.00161	CcSEcCtD
Lisuride—Cough—Doxorubicin—pancreatic cancer	0.000609	0.00161	CcSEcCtD
Lisuride—Nervous system disorder—Epirubicin—pancreatic cancer	0.000603	0.00159	CcSEcCtD
Lisuride—Dizziness—Docetaxel—pancreatic cancer	0.000603	0.00159	CcSEcCtD
Lisuride—Tachycardia—Epirubicin—pancreatic cancer	0.0006	0.00158	CcSEcCtD
Lisuride—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000595	0.00157	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—pancreatic cancer	0.000592	0.00156	CcSEcCtD
Lisuride—Anorexia—Epirubicin—pancreatic cancer	0.000586	0.00155	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—pancreatic cancer	0.000581	0.00153	CcSEcCtD
Lisuride—Vomiting—Docetaxel—pancreatic cancer	0.00058	0.00153	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—pancreatic cancer	0.000574	0.00151	CcSEcCtD
Lisuride—Headache—Docetaxel—pancreatic cancer	0.000571	0.00151	CcSEcCtD
Lisuride—Infection—Doxorubicin—pancreatic cancer	0.000565	0.00149	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000558	0.00147	CcSEcCtD
Lisuride—Insomnia—Epirubicin—pancreatic cancer	0.000556	0.00147	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—pancreatic cancer	0.000555	0.00147	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.00055	0.00145	CcSEcCtD
Lisuride—Dyspnoea—Epirubicin—pancreatic cancer	0.000548	0.00145	CcSEcCtD
Lisuride—Somnolence—Epirubicin—pancreatic cancer	0.000547	0.00144	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—pancreatic cancer	0.000543	0.00143	CcSEcCtD
Lisuride—Decreased appetite—Epirubicin—pancreatic cancer	0.000535	0.00141	CcSEcCtD
Lisuride—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000531	0.0014	CcSEcCtD
Lisuride—Fatigue—Epirubicin—pancreatic cancer	0.00053	0.0014	CcSEcCtD
Lisuride—Constipation—Epirubicin—pancreatic cancer	0.000526	0.00139	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—pancreatic cancer	0.000515	0.00136	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—pancreatic cancer	0.000507	0.00134	CcSEcCtD
Lisuride—Feeling abnormal—Epirubicin—pancreatic cancer	0.000507	0.00134	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—pancreatic cancer	0.000506	0.00133	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—pancreatic cancer	0.000495	0.00131	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000491	0.0013	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—pancreatic cancer	0.000491	0.00129	CcSEcCtD
Lisuride—Constipation—Doxorubicin—pancreatic cancer	0.000487	0.00128	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000469	0.00124	CcSEcCtD
Lisuride—Asthenia—Epirubicin—pancreatic cancer	0.000441	0.00116	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—pancreatic cancer	0.000408	0.00108	CcSEcCtD
Lisuride—Dizziness—Epirubicin—pancreatic cancer	0.000407	0.00107	CcSEcCtD
Lisuride—Vomiting—Epirubicin—pancreatic cancer	0.000391	0.00103	CcSEcCtD
Lisuride—Headache—Epirubicin—pancreatic cancer	0.000385	0.00102	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—pancreatic cancer	0.000376	0.000993	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—pancreatic cancer	0.000362	0.000955	CcSEcCtD
Lisuride—Headache—Doxorubicin—pancreatic cancer	0.000357	0.000941	CcSEcCtD
Lisuride—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	2.09e-05	3.62e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—NRAS—pancreatic cancer	2.08e-05	3.61e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	2.08e-05	3.61e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	2.08e-05	3.61e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	2.08e-05	3.61e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	2.08e-05	3.61e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.07e-05	3.6e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.07e-05	3.59e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	2.07e-05	3.59e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	2.07e-05	3.58e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	2.07e-05	3.58e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	2.06e-05	3.57e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—STAT3—pancreatic cancer	2.06e-05	3.57e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.06e-05	3.57e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—APOE—pancreatic cancer	2.06e-05	3.57e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MYC—pancreatic cancer	2.06e-05	3.57e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	2.05e-05	3.56e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—NRAS—pancreatic cancer	2.05e-05	3.56e-05	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	2.05e-05	3.56e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	2.05e-05	3.56e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	2.05e-05	3.56e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	2.05e-05	3.55e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	2.05e-05	3.55e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GCG—pancreatic cancer	2.04e-05	3.55e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.04e-05	3.54e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	2.03e-05	3.53e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	2.03e-05	3.52e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—AKT1—pancreatic cancer	2.02e-05	3.51e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	2.02e-05	3.51e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	2.02e-05	3.5e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	2.01e-05	3.49e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	2.01e-05	3.49e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	2.01e-05	3.48e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	2.01e-05	3.48e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.01e-05	3.48e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	2e-05	3.46e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.99e-05	3.45e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—KRAS—pancreatic cancer	1.99e-05	3.45e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	1.98e-05	3.43e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	1.96e-05	3.4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	1.96e-05	3.4e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.96e-05	3.4e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	1.95e-05	3.39e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.95e-05	3.38e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	1.95e-05	3.38e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—SRC—pancreatic cancer	1.94e-05	3.37e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	1.94e-05	3.37e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—pancreatic cancer	1.94e-05	3.36e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	1.93e-05	3.36e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	1.93e-05	3.34e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	1.93e-05	3.34e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	1.92e-05	3.33e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—STK11—pancreatic cancer	1.92e-05	3.33e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	1.91e-05	3.32e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	1.91e-05	3.32e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—pancreatic cancer	1.91e-05	3.32e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	1.91e-05	3.31e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	1.91e-05	3.31e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	1.91e-05	3.31e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	1.9e-05	3.3e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.9e-05	3.29e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—pancreatic cancer	1.9e-05	3.29e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	1.89e-05	3.29e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	1.89e-05	3.29e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	1.89e-05	3.28e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—pancreatic cancer	1.89e-05	3.27e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.88e-05	3.27e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	1.88e-05	3.26e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	1.88e-05	3.25e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—pancreatic cancer	1.87e-05	3.25e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	1.87e-05	3.25e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	1.87e-05	3.25e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—pancreatic cancer	1.87e-05	3.25e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	1.86e-05	3.23e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.86e-05	3.23e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—SRC—pancreatic cancer	1.86e-05	3.23e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	1.86e-05	3.22e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.86e-05	3.22e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.86e-05	3.22e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	1.85e-05	3.22e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.85e-05	3.21e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	1.84e-05	3.2e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—pancreatic cancer	1.84e-05	3.18e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	1.83e-05	3.17e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—pancreatic cancer	1.82e-05	3.17e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.82e-05	3.17e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	1.81e-05	3.14e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	1.81e-05	3.13e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.8e-05	3.13e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	1.8e-05	3.12e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—pancreatic cancer	1.8e-05	3.12e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	1.8e-05	3.11e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	1.79e-05	3.11e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—pancreatic cancer	1.79e-05	3.11e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.79e-05	3.11e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	1.79e-05	3.1e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.78e-05	3.1e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.78e-05	3.09e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.78e-05	3.08e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	1.77e-05	3.07e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—pancreatic cancer	1.77e-05	3.07e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—pancreatic cancer	1.77e-05	3.07e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	1.77e-05	3.07e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—pancreatic cancer	1.77e-05	3.07e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—pancreatic cancer	1.76e-05	3.06e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	1.76e-05	3.05e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.75e-05	3.04e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	1.75e-05	3.04e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.75e-05	3.03e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	1.74e-05	3.02e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—pancreatic cancer	1.74e-05	3.02e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.74e-05	3.02e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	1.74e-05	3.02e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	1.74e-05	3.01e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	1.73e-05	3.01e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	1.73e-05	3e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	1.73e-05	3e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	1.73e-05	2.99e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	1.72e-05	2.99e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	1.72e-05	2.98e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	1.72e-05	2.98e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	1.71e-05	2.96e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	1.7e-05	2.96e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	1.7e-05	2.96e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.69e-05	2.94e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—pancreatic cancer	1.69e-05	2.93e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	1.69e-05	2.93e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	1.69e-05	2.93e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.69e-05	2.93e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.68e-05	2.91e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—pancreatic cancer	1.67e-05	2.89e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	1.66e-05	2.89e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.66e-05	2.88e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.65e-05	2.87e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.65e-05	2.87e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.65e-05	2.86e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	1.64e-05	2.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.63e-05	2.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.63e-05	2.83e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.63e-05	2.83e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.63e-05	2.83e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.62e-05	2.82e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	1.62e-05	2.82e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.62e-05	2.81e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.62e-05	2.81e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.61e-05	2.8e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	1.61e-05	2.8e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	1.61e-05	2.79e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	1.61e-05	2.79e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.61e-05	2.79e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	1.6e-05	2.77e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—pancreatic cancer	1.59e-05	2.76e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.59e-05	2.76e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	1.59e-05	2.75e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.59e-05	2.75e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	1.58e-05	2.75e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	1.58e-05	2.74e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.58e-05	2.74e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.58e-05	2.73e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.57e-05	2.73e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	1.57e-05	2.73e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—pancreatic cancer	1.57e-05	2.73e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.57e-05	2.72e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	1.55e-05	2.69e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	1.55e-05	2.69e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1.55e-05	2.69e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	1.55e-05	2.68e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	1.54e-05	2.67e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	1.54e-05	2.67e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.53e-05	2.66e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—pancreatic cancer	1.52e-05	2.64e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	1.52e-05	2.63e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	1.5e-05	2.61e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—pancreatic cancer	1.5e-05	2.61e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—pancreatic cancer	1.49e-05	2.59e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	1.49e-05	2.59e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	1.48e-05	2.57e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	1.47e-05	2.54e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.47e-05	2.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.46e-05	2.54e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.46e-05	2.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.46e-05	2.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.44e-05	2.5e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.44e-05	2.49e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.43e-05	2.48e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—pancreatic cancer	1.43e-05	2.48e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	1.43e-05	2.47e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.42e-05	2.47e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.42e-05	2.47e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	1.42e-05	2.46e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.42e-05	2.46e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.41e-05	2.45e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.41e-05	2.44e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.41e-05	2.44e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.41e-05	2.44e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.41e-05	2.44e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.37e-05	2.38e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.37e-05	2.38e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	1.37e-05	2.37e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.36e-05	2.36e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	1.36e-05	2.35e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.35e-05	2.35e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.35e-05	2.34e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—pancreatic cancer	1.34e-05	2.33e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOE—pancreatic cancer	1.34e-05	2.33e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—pancreatic cancer	1.34e-05	2.32e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.33e-05	2.31e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.33e-05	2.31e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	1.33e-05	2.3e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—pancreatic cancer	1.33e-05	2.3e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	1.32e-05	2.3e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.31e-05	2.27e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.31e-05	2.27e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.31e-05	2.27e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	1.3e-05	2.26e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	1.3e-05	2.26e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.28e-05	2.22e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	1.27e-05	2.2e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	1.25e-05	2.16e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.24e-05	2.16e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.23e-05	2.13e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.22e-05	2.12e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.21e-05	2.1e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.21e-05	2.1e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	1.21e-05	2.1e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.2e-05	2.09e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	1.2e-05	2.08e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.18e-05	2.05e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.17e-05	2.03e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	1.16e-05	2.01e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	1.15e-05	2e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.15e-05	1.99e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.13e-05	1.96e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.12e-05	1.94e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.11e-05	1.93e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	1.1e-05	1.91e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.09e-05	1.89e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.08e-05	1.87e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.07e-05	1.85e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.03e-05	1.79e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.02e-05	1.76e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	9.99e-06	1.73e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	9.3e-06	1.61e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—pancreatic cancer	9.21e-06	1.6e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	9.09e-06	1.58e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	8.67e-06	1.5e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—pancreatic cancer	8.03e-06	1.39e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—pancreatic cancer	7.08e-06	1.23e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	5.67e-06	9.83e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—pancreatic cancer	4.63e-06	8.03e-06	CbGpPWpGaD
